Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:34:11.827Z.
Consensus retrieved: 2026-10-06T16:24:34.223Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:34:11.827Z.
Quote observation: 2026-10-06T17:30:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79812cd6dc1246c3578cfde2233ee829467ffef9b0062efd9074e0cc555abd58
Forward PE Ratio (N/A) = Dated Quote Price ($6.88) / Consensus Forward EPS ($-1.75)
FORWARD PE RATIO
N/A
Solid Biosciences Inc.
Market Cap
$676.84M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Solid Biosciences Inc. (SLDB) | $676.84M | N/A |
| Helus Pharma Inc. (HELP)vs › | $672.52M | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $689.08M | N/A |
| Annexon, Inc. (ANNX)vs › | $664.86M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $663.94M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $694.30M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $659.73M | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $697.03M | N/A |
| Starling Oncology, Inc. (STLN)vs › | $656.89M | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $701.23M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.88, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.75 | $-2.03 – $-1.63 | 10 | n/m |
| 2027-12-31 | $-1.69 | $-2.38 – $-1.36 | 10 | n/m |
| 2028-12-31 | $-1.24 | $-1.90 – $-0.48 | 10 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
